Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.35 +0.6%	$12.00	$8.04 ▼ $28.05	$334.94M	2.3	434,978 shs	377,342 shs
ATAI atai Life Sciences	$2.33 +5.0%	$1.82	$1.03 ▼ $2.64	$466.79M	1.48	1.71 million shs	3.08 million shs
AURA Aura Biosciences	$6.10 -1.3%	$5.84	$4.35 ▼ $12.38	$306.64M	0.42	210,365 shs	158,942 shs
GNTA Genenta Science	$3.11 -4.9%	$4.08	$2.79 ▼ $7.28	$56.88M	0.73	15,194 shs	33,187 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+0.57%	-0.72%	+3.00%	-3.82%	-52.43%
ATAI atai Life Sciences	+4.95%	+4.48%	+26.63%	+70.07%	+83.46%
AURA Aura Biosciences	-1.29%	-7.99%	+3.04%	-17.79%	-13.48%
GNTA Genenta Science	-4.89%	-18.59%	-28.90%	-20.66%	-3.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	3.0311 of 5 stars	4.6	0.0	2.7	2.5	0.6
ATAI atai Life Sciences	3.1459 of 5 stars	3.7	3.0	2.8	2.5	0.6
AURA Aura Biosciences	1.9147 of 5 stars	3.6	1.0	1.1	3.3	0.0
GNTA Genenta Science	2.9869 of 5 stars	3.5	5.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	333.20% Upside
ATAI atai Life Sciences	3.33	Buy	$8.67	271.96% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	260.66% Upside
GNTA Genenta Science	3.00	Buy	$25.00	703.86% Upside

Current Analyst Ratings Breakdown

Latest GNTA, ARCT, AURA, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/26/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.20	N/A	N/A	$8.90 per share	1.39
ATAI atai Life Sciences	$310K	1,505.78	N/A	N/A	$0.69 per share	3.38
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$0.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/8/2025 (Estimated)
GNTA Genenta Science	-$9.64M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest GNTA, ARCT, AURA, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
ATAI atai Life Sciences	0.08	4.07	4.07
AURA Aura Biosciences	N/A	11.06	11.06
GNTA Genenta Science	N/A	6.89	6.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
ATAI atai Life Sciences	28.41%
AURA Aura Biosciences	96.75%
GNTA Genenta Science	15.13%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
ATAI atai Life Sciences	26.80%
AURA Aura Biosciences	5.40%
GNTA Genenta Science	28.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable

GNTA, ARCT, AURA, and ATAI Headlines

Recent News About These Companies

Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 31.0% in May

June 17 at 9:29 AM | marketbeat.com

Reviewing Vaxcyte (NASDAQ:PCVX) and Genenta Science (NASDAQ:GNTA)

June 13, 2025 | americanbankingnews.com

Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Update

June 4, 2025 | marketbeat.com

GNTA Genenta Science S.p.A.

May 30, 2025 | seekingalpha.com

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025 | newsfilecorp.com

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

May 7, 2025 | globenewswire.com

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

April 15, 2025 | globenewswire.com

Genenta Science announces EUR 20M financing to expand pipeline

March 21, 2025 | markets.businessinsider.com

Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research

March 19, 2025 | tipranks.com

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

March 19, 2025 | globenewswire.com

Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?

February 13, 2025 | msn.com

Genenta Science SpA ADR

February 1, 2025 | investing.com

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

January 28, 2025 | prnewswire.com

Genenta Science announces amendment to pact with AGC Biologics

January 10, 2025 | finance.yahoo.com

Genenta, AGC Biologics Strengthen Cell Therapy Manufacturing Pact

January 9, 2025 | contractpharma.com

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

January 9, 2025 | globenewswire.com

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

January 8, 2025 | prnewswire.com

Genenta Science Enhances Manufacturing Agreement with AGC Biologics

January 1, 2025 | markets.businessinsider.com

Genenta Science Updates ATM Sales Agreement with New Agent

December 20, 2024 | tipranks.com

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

October 23, 2024 | globenewswire.com

Genenta Science (NASDAQ:GNTA) Stock Quotes, Forecast and News Summary

October 11, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA, ARCT, AURA, and ATAI Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.35 +0.07 (+0.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$12.70 +0.35 (+2.80%)

As of 06/18/2025 07:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

atai Life Sciences NASDAQ:ATAI

$2.33 +0.11 (+4.95%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.35 +0.02 (+0.86%)

As of 06/18/2025 07:56 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aura Biosciences NASDAQ:AURA

$6.10 -0.08 (-1.29%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$6.10 +0.01 (+0.08%)

As of 06/18/2025 04:04 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Genenta Science NASDAQ:GNTA

$3.20 -0.08 (-2.29%)

As of 06/18/2025 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time